A closer look at “Why Eli Lilly, Pfizer, and FDA Officials Are Finally Taking Longevity Medicine Seriously”, exactly as the source publishes it. After years of skepticism, pharmaceutical giants and regulators are now investing heavily in longevity science. At a recent industry conference, executives from Eli Lilly, Pfizer, and emerging biotech firms met with FDA officials to discuss the future of aging-related therapies, marking a significant shift in how the medical establishment approaches growing old. The three-day gathering revealed a consensus that aging itself may be treatable, with drugs targeting cellular senescence, metabolic dysfunction, and chronic inflammation moving closer to reality.
For patients, this could mean not just longer lives, but healthier ones, with fewer years lost to disease and disability. For the industry, it opens a market of billions of aging consumers. The FDA's presence signals a willingness to create regulatory pathways for therapies that don't fit the traditional disease model. For the complete material, the listing points back to the source inside the network.